ATTI 26° CONVEGNO NAZIONALE AIRM
17 February 2025
Vol. 42 No. 4 (2020)
https://doi.org/10.4081/gimle.470

[THE RISK OF SECOND RADIATION-INDUCED CANCER FROM HADRONTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY]

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
21
Views
23
Downloads

Authors

Angelica Facoetti
angelica.facoetti@cnao.it
Dipartimento Ricerca e Sperimentazione, Fondazione CNAO, Pavia, Italy.

Radiation therapy increasingly plays a fundamental role in the treatment of cancer. Since the survival of cancer patients is continuously improving, the late effects of treatments, including those related to radiation treatment, can affect the quality of life and health and of the patients themselves to a greater extent. Especially in the last 20 years, with the implementation of new techniques/forms of radiation therapy, the risk of developing radiation-induced tumors following radiation therapy has become a hotly debated topic. Malignant tumors induced by radiation therapy represent a particularly important problem for pediatric patients, who are intrinsically more sensitive to carcinogens than adults and have a longer life expectancy. To date, there is only one study in the literature, from 2019, which analyzes the risk of secondary tumors after carbon ion radiation compared to surgery or photon treatment and refers to patients treated for prostate cancer. Despite the high degree of uncertainty, the data acquired so far suggest that particle radiation therapy, especially with protons delivered with active scanning, carries a lower risk of G Ital Med Lav Erg 2020; 42:4 radiation-induced tumors than conventional photon therapies. This is largely due to the lower doses to which healthy tissues are exposed and the low relative risk associated with exposure to neutrons throughout the body, especially when active scanning beams are used.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Bekelman JE, Schultheiss T. Berrington de Gonzalez A. Editorial Subsequent malignancies after proton versus photon radiation therapy. Int J Radiat Oncol Biol 87:1-3, 2013. DOI: https://doi.org/10.1016/j.ijrobp.2013.05.016
Blyth BJ, Kakinuma S, Sunaoshi M, Amasaki Y, Hirano-Sakairi S, Ogawa K, Shirakami A, Shang Y, Isuruoka C, Nishimura M, Shimada Y. Genetic Analysis of T Cell Lymphomas in Carbon lonIrradiated Mice Reveals Frequent Interstitial Chromosome Deletions: Implications for Second Cancer Induction in Normal Tissues during Carbon Ion Radiotherapy. PLoS One 30;10(6):e0130666, 2015. DOI: https://doi.org/10.1371/journal.pone.0130666
Braunstein S and Nakamura JL. Radiotherapy-induced malignancies: review of clinical features, pathobiology, and evolving approaches for mitigating risk. Front Oncol 3:73, 2013. DOI: https://doi.org/10.3389/fonc.2013.00073
Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1:3-29, 1948. DOI: https://doi.org/10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7
Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 87:46-52, 2013. Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys 38:667 - 672, 1997. DOI: https://doi.org/10.1016/S0360-3016(97)00012-6
Hall EJ, Wuu C. Radiation-induced second cancers: The impact of 3DCRT and IMRT. Int J Radiat Oncol Biol Phys 56:83-88, 2003. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int. J. Radiation Oncology Biol Phys 65:1-7, 2006. DOI: https://doi.org/10.1016/S0360-3016(03)00073-7
Kong EY, Yeung WK, Chan TK, Cheng SH, Yu KN. Exogenous Nitric Oxide Suppresses in Vivo X-ray-Induced Targeted and NonTargeted Effects in Zebrafish Embryos. Int J Mol Sci 12;17(8), 2016. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen I1. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62:1195-1203, 2005. DOI: https://doi.org/10.1016/j.ijrobp.2005.03.053
Mohamad O, Tabuchi T, Nitta Y, Nomoto A, Sato A, Kasuya G, Makishima H, Choy H, Yamada S, Morishima T, Tsuji H, Miyashiro I, Kamada T. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study. Lancet Oncol 2019 Published online. DOI: https://doi.org/10.1016/S1470-2045(18)30931-8
Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98:1528-37, 2006. DOI: https://doi.org/10.1093/jnci/djj411
Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 11:438-48, 2011. DOI: https://doi.org/10.1038/nrc3069
Mancuso M, Pasquali E, Leonardi S, Tanori M, Rebessi S, Di Majo V, Pazzaglia S, Toni MP, Pimpinella M, Covelli V, Saran A. Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum. Proc Natl Acad Sci USA 105: 12445-12450, 2008. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, Li FP, Meadows AT, Mulvihill JJ, Neglia JP, Nesbit ME, Packer RJ, Potter JD, Sklar CA, Smith MA, Stovall M, Strong LC, Yasui Y, Zeltzer LK. Study design and cohort characteristics of the childhood cancer survivor study: a multi-institutional collaborative project. Med Pediatr Oncol 38:229-39, 2002. DOI: https://doi.org/10.1073/pnas.0804186105
Rusin A, Lapied E, Le M, Seymour C, Oughton D, Haanes H, Mothersill C. Effect of gamma radiation on the production of bystander signals from three earthworm species irradiated in vivo. Environ Res 168:211-221, 2019. DOI: https://doi.org/10.1016/j.envres.2018.09.023
Shuryak I, Sachs RK, Brenner DJ. A new view of radiation-induced cancer. Radiat Prot Dosimetry 143:358-64, 2011. DOI: https://doi.org/10.1093/rpd/ncq389
Shuryak I, Sachs RK, Brenner DJ. Cancer risks after radiation exposure in middle age. J Natl Cancer Inst 102:1628-36, 2010. DOI: https://doi.org/10.1093/jnci/djq346
Trott KR. Special radiobiological features of second cancer risk after particle radiotherapy. Physica Medica 42: 221-227, 2017. DOI: https://doi.org/10.1016/j.ejmp.2017.05.002
Tukenova M, Guibout C, Hawkins M, Quiniou E, Mousannif A, Pacquement H, Winter D, Bridier A, Lefkopoulos D, Oberlin O, Diallo I, de Vathaire F. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys 80:339-48, 2011. DOI: https://doi.org/10.1016/j.ijrobp.2010.02.004
Verellen D, Vanhavere F. Risk assessment of radiation induced malignancies based on whole-body dose equivalent estimates for IMRT in the head and neck region. Radiother Oncol 53:199-203, 1999. DOI: https://doi.org/10.1016/S0167-8140(99)00079-1
Wang T, Xu W, Deng C, Xu S, Li F, Wu Y, Wu L, Bian P. A pivotal role of the jasmonic acid signal pathway in mediating radiation-induced bystander effects in Arabidopsis thaliana. Mutat Res 791-792:1-9, 2016. DOI: https://doi.org/10.1016/j.mrfmmm.2016.07.002

How to Cite



[THE RISK OF SECOND RADIATION-INDUCED CANCER FROM HADRONTHERAPY VERSUS CONVENTIONAL RADIOTHERAPY]. (2025). Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia, 42(4), 252-256. https://doi.org/10.4081/gimle.470
Copyright (c) 2020 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.